Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment
Publication date
2022-11
Authors
Verkerk, Karlijn
Otten, Hans-Martin
Huitema, Alwin D R
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Idiopathic hyperammonemic encephalopathy is a rare complication of chemotherapy, which has previously mainly been associated with L-asparaginase, cytarabine and 5-FU. We present a case following treatment with gemcitabine-cisplatin in a patient with cholangiocarcinoma. The etiology of chemotherapy-induced idiopathic hyperammonemic encephalopathy remains unclear and existing theories differ per chemotherapeutic agent. Physicians treating patients with gemcitabine-cisplatin should be aware of the possibility of this complication, especially because it is treatable when recognized early.
Keywords
Antineoplastic Agents/therapeutic use, Asparaginase/therapeutic use, Brain Diseases/chemically induced, Cisplatin, Cisplatin/adverse effects, Cytarabine/adverse effects, Deoxycytidine/analogs & derivatives, Fluorouracil, Gemcitabine, Humans, Hyperammonemia, Hyperammonemia/chemically induced, Hyperammonemic encephalopathy, Neurotoxicity Syndromes/drug therapy, Taverne, Case Reports, Journal Article
Citation
Verkerk, K, Otten, H-M & Huitema, A D R 2022, 'Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment', Cancer Chemotherapy and Pharmacology, vol. 90, no. 5, pp. 417-419. https://doi.org/10.1007/s00280-022-04476-6